DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
DiaMedica Therapeutics enrolled its 200th patient in a Phase 2/3 stroke treatment trial, enabling a planned interim analysis.· summarised by Stockedin
DMAC